Zyga Technology has received the US Food & Drug Administration (FDA) 510(K) clearance to market its SImmetry Sacroiliac Joint Fusion System, for treating degenerative sacroiliitis and sacroiliac joint disruptions.
The SImmetry Sacroiliac Joint Fusion System consists of a range of threaded, cannulated implants and associated instrumentation.
The implants are designed to transfix the sacrum and ilium, providing stability for bony fusion.
Prairie Spine & Pain Institute Orthopedic Surgery chief Richard Kube said SImmetry is a welcome addition to his practice because it gives patients suffering from sacroiliac joint dysfunction a minimally invasive surgical treatment option.
"The SImmetry system allows surgeons to prepare the SI joint for a true arthrodesis," Kube said.
Zyga Technology president and CEO Robert Assell said they are excited for this important milestone.
"Increased awareness of SI joint disruption as a significant contributor to low back pain led us to develop a minimally invasive solution to treat this condition," Assell said.